Patent classifications
C07D209/26
4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof
The present invention relates to compounds according to Formula I (Formula I), and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions. ##STR00001##
4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof
The present invention relates to compounds according to Formula I (Formula I), and pharmaceutically acceptable salts or solvates thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions. ##STR00001##
Derivatives of indole for the treatment of cancer, viral infections and lung diseases
The present invention relates to a new class of indole derivatives, having a particular MKlp2 inhibition profile and useful as a therapeutic agent, in particular for the treatment of cancer, viral infections and lung diseases.
Derivatives of indole for the treatment of cancer, viral infections and lung diseases
The present invention relates to a new class of indole derivatives, having a particular MKlp2 inhibition profile and useful as a therapeutic agent, in particular for the treatment of cancer, viral infections and lung diseases.
FLUORINATED TRYPTAMINE COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME
The present disclosure relates in one aspect to fluorinated tryptamine compounds, or analogues thereof, and compositions comprising the same. Compounds of the disclosure can be used to treat, prevent, and/or ameliorate a psychiatric disease or disorder in a subject.
FLUORINATED TRYPTAMINE COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME
The present disclosure relates in one aspect to fluorinated tryptamine compounds, or analogues thereof, and compositions comprising the same. Compounds of the disclosure can be used to treat, prevent, and/or ameliorate a psychiatric disease or disorder in a subject.
USP30 INHIBITORS AND USES THEREOF
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.
TAK1 kinase inhibitors, compositions, and uses related thereto
The disclosure relates to TAK1 inhibitors, compositions, and uses related thereto. In certain embodiments, the disclosure relates to compounds of formula I, pharmaceutical compositions having a compound of formula I, and methods of treating or preventing cancer by administering an effective amount of a pharmaceutical composition having a compound of formula I to a subject in need thereof.
TAK1 kinase inhibitors, compositions, and uses related thereto
The disclosure relates to TAK1 inhibitors, compositions, and uses related thereto. In certain embodiments, the disclosure relates to compounds of formula I, pharmaceutical compositions having a compound of formula I, and methods of treating or preventing cancer by administering an effective amount of a pharmaceutical composition having a compound of formula I to a subject in need thereof.
INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER
Provided are compositions for inhibiting a biological activity of an aldo-keto reductase family 1, member C3 (AKR1C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have AKR1C3 inhibitory activity, methods for inhibiting AKR1C3 polypeptide biological activities, and methods for treating prostate tumors in subjects.